The Group possesses strong R&D capabilities and a rich product pipeline. The Central Drug Research Institute, located at CSPC’s headquarters, is formed by a strong professional team of overseas returnees and staff with PhDs and Master’s degrees. Currently, the Group has over 300 projects in the pipeline including Class 1 new drugs, Class 3 news drugs and new preparations, with focus on five major therapeutic areas of cardio-cerebrovascular, metabolic diseases (such as diabetes), oncology, psychiatry and neurology, as well as anti-infection. With regard to overseas registrations, “levamlodipine maleate tablets” has submitted NDA to the U.S. FDA, and several drugs have been granted the orphan drug designations in U.S.. The Group will continue to conduct clinical trials of small molecule new drugs and actively prepare ANDA in U.S. in order to expand overseas market.
CSPC implements the innovation-driven strategy by continuously investing in research and development and coping internal development with external cooperation to enhance the drive for innovation. This ensures that the performance of the Group will continue to grow and greater contributions could be made to the shareholders and the community.